**Core tip:** High dose intravenous vitamin C (VitC) is often used by Complementary and Alternate Medicine practitioners for a variety of ailments. Moreover, use of high dose VitC by mainstream physicians as an adjunct in the treatment of sepsis, sepsis induced acute lung injury, cancer and burns is on the rise. However, there is no information on the impact of these high doses VitC on normal platelet (PLT) function. Prolonged exposure of *ex vivo* PLTs to high doses of VitC altered some PLT functions as assessed by thromboelastography. However, short term exposure (\< 8 d) or low dose exposure had almost no impact on PLT function.

INTRODUCTION
============

Platelets (PLTs) are central to physiologic processes involved in hemostasis and thrombosis\[[@B1]\]. While an immune function of PLTs has been described in the literature\[[@B2]\], recent studies point to an incompletely understood role for PLTs in a myriad of host immune responses. These studies point to altered PLT function in numerous disease states including inflammation, acute respiratory distress syndrome, atherosclerosis and cancer\[[@B3]-[@B5]\].

L-ascorbic acid is the reduced form of vitamin C (VitC). It is a water soluble molecule with strong antioxidant properties\[[@B6],[@B7]\]. PLTs possess Na^+^-dependent VitC transporters (SVCT2) and this allows them to actively transport VitC intracellularly\[[@B8]\]. Although normal VitC concentrations in plasma are 50-80 μmol/L, PLTs can hold up to 4 mmol/L of intracellular VitC\[[@B9]\]. This is 50-80 fold higher than circulating VitC concentrations in plasma\[[@B10]\]. Studies have shown that VitC plays several roles in platelet functions, including reduction of reactive oxygen species\[[@B11]\], inhibition of expression of the pro-inflammatory CD40 ligand (CD40L)\[[@B12]\], inhibition of thromboxane B~2~ formation\[[@B13]\] and stimulation of prostaglandin E~1~ production\[[@B14]\]. This underscores the important role of VitC for normal platelet metabolic functions.

While VitC at normal physiological concentrations is critical for PLT function, there is virtually no information on the impact of high concentrations of VitC on PLT function. High dose intravenous VitC was predominantly used by Complementary and Alternate Medicine (CAM) practitioners. However, there has been a recent trend to use high dose intravenous VitC to treat many chronic, untreatable or intractable disease states. At the present time, high dose intravenous VitC is often used as an adjunct in the treatment of sepsis, sepsis induced acute lung injury, cancer, iron deficiency in hemodialysis patients and even in the burn protocol\[[@B15]-[@B19]\]. A few studies have reported that high dose intravenous VitC has complications in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency. But, in general, its use appears relatively safe in multiple published randomized clinical trials. Yet, since the scale of such use is on the rise, it is vital that the safety of high dose VitC be examined in greater detail. To address this need, we examined the effect of exposing human PLTs to high doses of VitC. The doses used in this study were typically those reported in many of the recently completed randomized clinical trials\[[@B15]-[@B19]\]. We also used PLTs under *ex vivo* conditions for these studies. These PLTs were primarily collected for therapeutic or prophylactic transfusions and stored appropriately. We examined the effect of high doses VitC on a variety of PLT functions, both at rest and following activation, over an 8 d period.

MATERIALS AND METHODS
=====================

Platelet concentrate preparation
--------------------------------

Platelet concentrates (PCs) were prepared by Virginia Blood Services (Richmond, VA) following standard operating procedures. Briefly, freshly collected, whole blood was centrifuged at low speed (soft spin 1500 × g) to separate platelet rich plasma (PRP). PRP was subjected to a second centrifugation (hard spin 5000 × g), then all but 50 mL of supernatant plasma was removed to concentrate the PLTs. The PLTs were re-suspended in residual plasma and stored with agitation at 22 °C-24 °C for 8 d at the Virginia Commonwealth University Transfusion Medicine Center.

Experimental design and study groups
------------------------------------

PCs were treated with one of three additives: Normal saline (control); 0.3 mmol/L VitC (Lo VitC); or 3 mmol/L VitC (Hi VitC) as final concentrations. We used 6-10 PC's per treatment arm. The VitC additive was preservative-free buffered ascorbic acid in water (Ascor L500, McGuff Pharmaceuticals, Santa Ana, CA), pH 5.5 to 7.0 adjusted with sodium bicarbonate and sodium hydroxide. Prior to supplementation, an initial baseline sample was collected at the blood supplier facility and transported to participating laboratories for analysis. PCs that passed standard screening tests were transported to the Virginia Commonwealth University Transfusion Medicine Center and sampled again on days 2, 5 and 8.

Sample processing
-----------------

PLT samples were collected using sterile technique and processed. An initial PLT count was obtained and a portion of the sample was used to obtain platelet poor plasma (PPP) by centrifugation at 2000 × g for 10 min. The resultant PPP was then used to adjust the sample platelet concentration to 230-270 × 10^3^/ μL (Adj. PRP).

Platelet pH and ascorbate analysis
----------------------------------

An aliquot of the unadjusted PC was used for pH determination. For ascorbate determination, Adj. PRP (500 μL) was pelleted by centrifugation; washed with room temperature phosphate buffered saline; deproteinized in 100 μL of cold 20% trichloroacetic acid followed by addition of 100 μL of cold 0.2% dithiothreitol to prevent oxidation. Platelet lysates were vortexed and centrifuged at 10000 g for 10 min 4 °C. The supernatants were stored at -80 °C for batch analysis. Total ascorbate was assessed using a Tempol-OPDA based fluorescence end-point assay as previously described\[[@B20]\].

Plasma coagulation tests
------------------------

Aliquots of PPP were assayed for prothrombin time (PT), activated partial thromboplastin time, and functional fibrinogen using the Stago STA Compact Coagulation Analyzer (Diagnostica Stago Inc., Parsippany, NJ) according to manufacturer's instructions.

Measurement of platelet function
--------------------------------

**Viscoelastic properties measurement:** The viscoelastic properties of PRP were measured in duplicate on a thromboelastography analyzer \[thromboelastography (TEG) 5000, Haemonetics Corp., Braintree, maximum amplitude (MA)\] using published methods\[[@B21]\]. Briefly, 30 μL of 0.2 mmol/L CaCl~2~ and 330 μL of PRP were loaded into the TEG cup sequentially and test parameters (*i.e*., R, K, α and MA) recorded.

**Platelet aggregation and secretion:** PLT aggregation in response to 2 μg/mL collagen or 10 μmol/L adenosine diphosphate (ADP) stimulation was measured by optical density using PRP. Simultaneously, the associated PLT adenosine triphosphate (ATP) secretion was measured *via* luminescence using Chrono-Lume^TM^ reagent. Respective PPP aliquots of each sample were used as blanks. All runs were done in duplicate on a Chrono-log Series 500 aggregometer (Chrono-Log Corp., Havertown, PA) according to manufacturer's instructions.

Platelet flow cytometry
-----------------------

**Reagents:** Human thrombin (T7009), Gly-Pro-Arg-Pro (GPRP) tetra-peptide inhibitor of fibrin polymerization, and serum bovine albumin were all obtained from Sigma-Aldrich (St. Louis, MO); phosphate-buffered saline and formalin from Beckman Coulter (Fullerton, CA); fluorescein isothiocynate conjugated CD41a (CD41a-FITC) and CD-31 (CD31-FITC), and phycoerythrin conjugated CD62p (CD62p-PE) and CD63 (CD63-PE) were obtained from BD Biosciences (San Jose, CA); ADP from Chrono-Log Corp (Havertown, PA).

**Procedure:** Adj. PRP was diluted (1:10) using sterile saline (0.9% NaCl). Eight tubes were prepared per sample; 1 unstained, 3 CD62p-PE (alone, thrombin 0.5 U/mL, or ADP 10 μmol/L), 3 CD63-PE (alone, thrombin 0.5 U/mL, or ADP 10 μmol/L), and 1 containing the corresponding isotypes-matched monoclonal antibodies mixture (negative control). CD41a-FITC and/or CD31-FITC were used to set the platelets gate for acquisition. GPRP (0.5 mmol/L) was added prior to thrombin activation to inhibit fibrin polymerization. All tubes were processed the same day on the Accuri C6 flow cytometer (BD Biosciences, San Jose, CA). The assay was performed under the following conditions: Fluidics: Medium; forward scatter threshold: 30000; and 20000 events were collected in a preset platelet gate using standard methods including CD41a and/or CD31 as global platelet markers. The collected data were analyzed using FlowJo version 7.6.5. (Ashland, OR). Results were expressed in mean fluorescence intensity units for CD41 and in percentages for other markers of activation.

Lipidomics analysis
-------------------

Eicosanoids were analyzed as previously described\[[@B22]-[@B24]\]. Quantitative analysis of the lipids in the ethanolic extracts was carried out using UPLC ESI-MS/MS as described with minor modifications\[[@B25],[@B26]\]. Briefly, to 200 μL of plasma, LCMS grade ethanol containing 10 ng of each internal standard was added (1 mL). The samples were mixed using a bath sonicator followed by incubation overnight at -20 °C for lipid extraction. Following incubation, the insoluble fraction was precipitated by centrifuging at 12000 g for 20 min and the supernatant was transferred into a new glass tube. The lipid extracts were then dried under vacuum and reconstituted in LCMS grade 50:50 EtOH:dH~2~O (100 μL) for eicosanoid quantitation *via* UPLC ESI-MS/MS analysis.

Statistical analysis
--------------------

Statistical analysis was performed using SAS 9.3 and GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, United States) by Bernard J Fisher, Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia and Bassem M. Mohammed, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, Virginia. Data are expressed as mean ± SE. Results were compared by one-way ANOVA and the *post hoc* Tukey test to identify specific differences between groups. Statistical significance was confirmed at a *P* value of \< 0.05.

RESULTS
=======

VitC exposure increased intracellular PLT VitC concentrations during storage
----------------------------------------------------------------------------

Freshly isolated PLTs contain high concentrations of intracellular VitC (1.23 ± 0.09 mmol/L). These concentrations are about 20 fold higher than the typical plasma levels of 50-80 μmol/L VitC. In freshly isolated PLTs on day 0, intracellular platelet VitC concentrations were not significantly different between the groups (Figure [1](#F1){ref-type="fig"}). By day 2, PLTs from VitC supplemented bags had significantly higher VitC levels (3.2 mmol/L for Lo VitC and 15.7 mmol/L for Hi VitC) compared to saline (1.2 mmol/L, *P* \< 0.05). VitC content of PLTs observed at day 2 did not significantly change throughout the rest of the storage period in all three groups. This suggests that PLTs, when exposed to high concentrations of VitC, have the capacity to store VitC intracellularly at concentrations that are significantly higher than that observed at normal plasma levels.

![Vitamin C exposure increased intracellular platelet vitamin C concentrations during storage. PLTs supplemented with Lo/Hi VitC had significantly higher intracellular levels of VitC (3.2 mmol/L for Lo VitC and 15.7 mmol/L for Hi VitC) compared to saline controls (1 mmol/L), (*n* = 10/group, ^a^*P* \< 0.05). VitC: Vitamin C; PLTs: Platelets.](WJCCM-6-37-g001){#F1}

VitC exposure was associated with pH drop on day 8
--------------------------------------------------

Baseline pH was initially identical between the three groups. There was a slow, but comparable drop in pH in the three groups until day 5. However, in the PC exposed to Lo/Hi VitC supplementation, there was a further significant decrease in pH between day 5 and day 8 (Figure [2](#F2){ref-type="fig"}, *P* \< 0.05).

![Vitamin C exposure was associated with pH drop on day 8. The addition of Lo/Hi VitC did not alter the pH of the platelet concentrate. Changes in pH were comparable throughout day 5 of storage. Both Lo/Hi VitC were associated with a further significant decrease in pH between day 5 and day 8 (*n* = 6/group, ^a^*P* \< 0.05). VitC: Vitamin C; PLTs: Platelets.](WJCCM-6-37-g002){#F2}

VitC exposure did not alter coagulation pathways in PLTs
--------------------------------------------------------

VitC supplementation did not significantly change PT and PTT values which gradually increased in all three groups (Figure [3A](#F3){ref-type="fig"} and B). On similar lines, functional fibrinogen levels also did not differ between the groups over the 8 d and remained within a clinically relevant range (Figure [3C](#F3){ref-type="fig"}).

![Vitamin C exposure did not alter coagulation pathways in platelets. PT, PTT and Fibrinogen were performed to detect major impacts on the intrinsic, extrinsic and common coagulation pathways. Using platelet poor plasma we observed no significant changes across the saline, Lo- and Hi VitC groups in the PT (A), PTT (B), and Fibrinogen (C) profiles over storage (*n* =10/group). VitC: Vitamin C; PT: Prothrombin time; PTT: Partial thrombplastin time.](WJCCM-6-37-g003){#F3}

High VitC exposure impacts PLT function on day 8
------------------------------------------------

Over the first 5 d, the addition of Hi or Lo VitC had no deleterious impact on any of the TEG parameters compared to the saline control (Figure [4](#F4){ref-type="fig"}). However, on day 8 significant differences were associated with extended storage in Hi VitC. Specifically, R and K times were extended in the Hi VitC group when compared to saline group (Figure [4A](#F4){ref-type="fig"} and B, *P* \< 0.05). In agreement with K-time data, a decrease in α-angle was observed in the Hi VitC group on day 8 (Figure [4C](#F4){ref-type="fig"}, *P* \< 0.05). On day 8, there was a fall of 20 mm in MA associated with the Hi VitC compared to both baseline and day 8 saline controls (Figure [4D](#F4){ref-type="fig"}, *P* \< 0.05).

![High vitamin C exposure impacts platelet function on day 8. No significant differences were observed between saline, Lo VitC and Hi VitC throughout the standard 5-d storage period in any of the TEG parameters analyzed (*n* = 10/group). On day-8, R- (A) and K- (B) times were extended in the Hi VitC group compared to saline (*n* = 10, ^a^*P* \< 0.05). Similar changes were observed for the α-angle (C) on day-8 (*n* = 10, ^a^*P* \< 0.05). The Hi VitC group was also associated with a significantly lower MA (D) on day-8 compared to the saline group (*n* = 10, ^a^*P* \< 0.05). VitC: Vitamin C; TEG: Thromboelastography.](WJCCM-6-37-g004){#F4}

Platelet aggregation studies, showed uniform declines in Collagen and ADP-induced platelet aggregations over the study period in all three groups (Figure [5A](#F5){ref-type="fig"} and B). In addition, Lo/Hi VitC addition did not alter Collagen and ADP-induced ATP secretion throughout the study (Figure [5C](#F5){ref-type="fig"} and D). Furthermore, flow cytometric analysis of CD62 and CD63 expression profiles, showed that VitC supplementation had no effect on basal CD62p and CD63 expression during storage (Figure [6A](#F6){ref-type="fig"} and D). Following ADP (Figure [6B](#F6){ref-type="fig"}) or thrombin (Figure [6C](#F6){ref-type="fig"}) stimulation, the CD62 expression showed a steady decrease that was not significantly different across the three groups (except for Hi VitC *vs* saline on day 8, *P* \< 0.05). The expression profiles for CD63 differed depending on whether the PC were stimulated with ADP or thrombin (Figure [6E](#F6){ref-type="fig"} and F). However, the observed flow cytometric analysis changes were not significant across the three groups over 8 d.

![Vitamin C exposure did not affect agonist-stimulated aggregation or adenosine triphosphate secretion by platelets. Using adj. PRP aliquots, addition of Lo/Hi VitC did not alter Collagen-induced PLTs aggregation (A) and ATP secretion (C) as well as ADP-induced PLTs aggregation (B) and ATP secretion (D) when compared to saline controls (*n* = 10/group). VitC: Vitamin C; PLTs: Platelets; ADP: Adenosine diphosphate; PRP: Platelet rich plasma; ATP: Adenosine triphosphate.](WJCCM-6-37-g005){#F5}

![Vitamin C exposure did not significantly alter basal or agonist-stimulated CD62 or CD63 expression profiles. Flow cytometry showed that basal expression of both CD62 (A) and CD63 (D) did not differ with the addition of Lo/Hi VitC. ADP-stimulated CD62 (B) expression was lower on day 8 in the Hi VitC group (*n* = 10/group, ^a^*P* \< 0.05), but CD63 (E) expression was not. Thrombin-stimulated CD62 (C) and CD63 (F) expression also did not differ across the three groups (*n* = 10/group). VitC: Vitamin C; ADP: Adenosine diphosphate.](WJCCM-6-37-g006){#F6}

Effects of VitC exposure on eicosanoids metabolism in PLTs
----------------------------------------------------------

Eicosanoids analysis was carried out on days 0, 2, 5 and 8 using aliquots of the PPP fraction of each sample. The levels of the free polyunsaturated fatty acids: Arachidonic acid (AA), eicosapentanoic acid (EPA), and docosahexanoic acid (DHA) did not differ significantly across the three groups throughout the study period (Figure [7A](#F7){ref-type="fig"}-C). Interestingly, free AA levels showed an initial drop from baseline in the three groups, and then remained unchanged through day 8. Formation of 11-/12-/15-HETE, products of AA metabolism *via* the lipoxygenases pathway showed a gradual increase over storage time (Figure [7D](#F7){ref-type="fig"}-F). The magnitudes of changes were not significantly different between the Lo VitC and the saline groups. However, levels of 11-HETE was significantly higher at days 5 and 8 in the Hi VitC group when compared to saline (Figure [7D](#F7){ref-type="fig"}, *P* \< 0.05). Hi VitC supplementation significantly augmented 12-HETE levels on days 2, 5 and 8 (Figure [7E](#F7){ref-type="fig"}, *P* \< 0.05). With respect to 15-HETE, only day 8 levels were significantly higher in the Hi VitC group compared to saline (Figure [7F](#F7){ref-type="fig"}, *P* \< 0.05). On similar lines, thromboxane B2 (TXB~2~) (the stable metabolite of TXA~2~) and prostaglandin E2 (PGE~2~), products of AA metabolism *via* the cyclooxygenases pathway were not significantly different between the Lo VitC and saline group. However, Hi VitC supplementation was associated with significantly higher TXB~2~ levels on days 5 and 8 (Figure [7G](#F7){ref-type="fig"}, *P* \< 0.05); and significantly higher PGE~2~ levels on days 2 and 8 compared to saline (Figure [7H](#F7){ref-type="fig"}, *P* \< 0.05).

![Hi vitamin C, but not Lo vitamin C exposure, was associated with significant changes in the eicosanoid profile over time. Addition of Lo/Hi VitC did not affect the levels of the PUFA: AA (A), EPA (B) and DHA (C) in comparison to saline controls (*n* = 10/group). Addition of Hi VitC was associated with significantly higher levels of 11-HETE (D) on days 5 and 8 (*n* = 10/group, ^a^*P* \< 0.05); 12-HETE (E) on days 2, 5 and 8 (*n* = 10/group, ^a^*P* \< 0.05); and 15-HETE (F) on day 8 (*n* = 10/group, ^a^*P* \< 0.05). TXB2 (G) was also significantly higher in the Hi VitC group on days 5 and 8 (*n* = 10/group, ^a^*P* \< 0.05). In addition, PGE~2~ levels (H) were significantly higher on days 2 and 8 in the Hi VitC group (*n* = 10/group, ^a^*P* \< 0.05). VitC: Vitamin C; PUFA: Polyunsaturated fatty acids; AA: Arachidonic acid; EPA: Eicosapentanoic acid; DHA: Docosahexanoic acid; TXB~2~: Thromboxane B2; PGE~2~: Prostaglandin E2.](WJCCM-6-37-g007){#F7}

DISCUSSION
==========

VitC is one of the most enduring and popular alternative medical treatments sought after. Beyond its oral use to treat scurvy, parenteral VitC has been used by CAM practitioners for more than 6 decades\[[@B27]-[@B29]\]. The most controversial use of high dose VitC as a cancer treatment was promoted by the Nobel Laureate, Cameron et al\[[@B30],[@B31]\]. Recently published evidence has demonstrated that intravenous, but not oral administration of VitC produces pharmacologic plasma concentrations of VitC\[[@B32]\]. This has elucidated possible mechanisms of action of intravenous VitC and for the first time made therapeutic effects, biologically plausible\[[@B33]\]. In the past few years this therapeutic option has been implemented most often as adjunct therapy in diverse conditions such as sepsis, infections, autoimmune diseases and cancers\[[@B15]-[@B19]\]. The basis for use of high dose intravenous VitC has been established in pre-clinical studies in which VitC modulated coagulopathies in disease states. For example, Swarbeck et al\[[@B34]\] showed that VitC attenuates plasminogen activator inhibitor-1 expression and release in an *in vitro* model of sepsis. On similar lines Secor et al\[[@B35]\] showed that VitC reduces mouse platelet aggregation and surface P-selectin expression in an *ex vivo* model of sepsis. However, to date, no studies have directly examined the effect of high doses of VitC on human PLT function. To address this, we asked the question whether exposure to high doses of VitC, as would normally be observed with high dose intravenous VitC therapy, have any effect on PLT function.

In our study we found that PLTs exposed to VitC rapidly accumulated millimolar quantities of VitC as early as day 2 and maintained these levels throughout the study period (Figure [1](#F1){ref-type="fig"}). Savini et al\[[@B8]\] showed that human PLTs possess the VitC transporter SVCT2, which enable PLTs to increase intracellular levels of VitC. Importantly, while PLTs typically have approximately 4 mmol/L intracellular VitC in normal plasma, exposure to 3 mmol/L VitC increased intracellular VitC levels to \> 15 mmol/L. This is significant, especially in cardiovascular pathologies since PLT activation and aggregation are modulated by reactive oxygen species\[[@B36]\]. VitC can alter the oxidative state of PLTs and inhibit the expression of CD40L, a transmembrane protein with pro-inflammatory and pro-thrombotic properties\[[@B12]\]. Indeed, oral administration of VitC has been reported to reduce arterial stiffness and platelet aggregation\[[@B37]\].

VitC did not alter the pH of the PC throughout the standard 5 day storage period when compared to saline controls (Figure [2](#F2){ref-type="fig"}). Unlike the saline treated PLTs whose pH stayed in the neutral range on day 8, there was a significant drop in pH in the VitC treated PLTs. However, it is unlikely that these pH changes would significantly alter blood pH due to presence of the carbonic acid-bicarbonate buffer, the phosphate buffer system, which consists of phosphoric acid (H~3~PO~4~) in equilibrium with dihydrogen phosphate ion (H~2~PO~4~^-^) and H^+^ and hemoglobin that play an important role in regulating the pH of the blood.

Our results show that the changes in PT, PTT and fibrinogen were comparable across the three groups throughout the study period and that exposure to high doses of VitC did not adversely impact these parameters (Figure [3](#F3){ref-type="fig"}). Only a few studies have employed TEG to evaluate functionality of human PLTs in the PC's\[[@B38]-[@B41]\]. However, unlike previous studies that adjusted PRP counts using freshly thawed PPP, we used same sample PPP to make adjustments. While TEG parameters across the three groups were comparable, some critical differences were observed on day 8 in the Hi VitC treated PLTs (Figure [4](#F4){ref-type="fig"}). The Hi VitC treated group showed a prolonged R-time, and a reduced MA as compared to the saline controls. Also, the Hi VitC groups had significantly delayed kinetics which was evidenced by prolonged K-times and reduced α-angle. It is unclear at this time why these changes occurred and future mechanistic approaches are needed to explain this finding. However, the corollary from these studies is that this inhibitory effect of VitC may have deleterious clinical implications if high dose VitC therapy is instituted for 8 d or more, or if plasma VitC levels are maintained at 3 mmol/L or higher for long periods of time.

Platelet aggregation studies show that Lo/Hi VitC addition did not alter the baseline or collagen and ADP-induced platelet aggregations (Figure [5A](#F5){ref-type="fig"} and B) and collagen and ADP-induced ATP secretion throughout the study (Figure [5C](#F5){ref-type="fig"} and D). Flow cytometry showed that VitC supplementation had no effect on basal CD62p and CD63 expression during storage (Figure [6A](#F6){ref-type="fig"} and D). Following ADP (Figure [6B](#F6){ref-type="fig"}) or thrombin (Figure [6C](#F6){ref-type="fig"}) stimulation, the CD62 expression showed a steady decrease that was not significantly different across the three groups (except for Hi VitC). Lo/Hi VitC induced changes in CD63 expression with ADP or thrombin (Figure [6E](#F6){ref-type="fig"} and F) were not significant over 8 d. These results imply that exposure of normal PLTs to high concentrations of VitC has virtually no impact on agonist induced platelet aggregation under these conditions.

Although we did not observe differences in the levels of free AA, EPA and DHA in the plasma of stored PCs, exposure to Hi VitC was associated with a significant increase in the levels of PGE~2~, TXB~2~, 11-, 12- and 15-HETE (Figure [7](#F7){ref-type="fig"}). Some of these free fatty acids (FFAs) have roles in host defense against potential pathogenic or opportunistic microorganisms. Indeed, there is extensive literature demonstrating the antibacterial effects of various free fatty acids from a wide range of biological sources including plants, animals and algae\[[@B42]\]. Whilst their antibacterial mode of action is still poorly understood, studies have shown that their prime target is the cell membrane where FFAs disrupt the electron transport chain and oxidative phosphorylation. Besides interfering with cellular energy production, FFA also inhibit enzyme activity, impair nutrient uptake, and participate in the generation of peroxidation and auto-oxidation degradation products or direct lysis of bacterial cells. While intravenous VitC has been shown to reduce bacterial burden and improve survival in pre-clinical models of sepsis\[[@B43]-[@B45]\] it remains to be determined whether the mechanism involves the induction of these FFAs.

As discussed above, both TXB~2~ and PGE~2~ levels were significantly higher in PLTs exposed to Hi VitC (Figure [7](#F7){ref-type="fig"}). Along with possible bacteriostatic effects, there are other potentially beneficial effects associated with induction of these metabolites. For example, a recent study by Bruegel et al\[[@B46]\] demonstrated that reduced release of 11-HETE, PGE~2~ and TXB~2~ was associated with increased disease severity and poor prognosis in septic patients. PGE~2~ plays a dual role balancing PLTs response by stimulation or suppression; and is more generally involved in fine tuning the pro-/anti-inflammatory response\[[@B47]\]. While TXA~2~ production is associated with PLTs activation, recent data have supported a protective role of TXA~2~ *via* its inhibitory regulation of iNOS in the vasculature. In this regard, TXA~2~ was found to overcome vascular hypo-responsiveness and help maintaining the vascular tone\[[@B48]\]. The increased production of 12- and 15-HETEs observed in Hi VitC treated bags may also be a protective mechanism against the significantly increased TXA~2~\[[@B49],[@B50]\]. In sum, exposure of PLTs to high doses of VitC alters endogenous production of lipid mediators by PLTs. These mediators could have unappreciated, yet far reaching impacts on not just PLTs function but on the entire circulatory system.

We recognize that our studies had a few limitations. PLTs in storage bags are not in their normal physiologic environment. They do not interact with endothelial cells or other cell types in these storage bags; they are highly concentrated; and also have access only to a finite amount of nutrients\[[@B51]\]. Accumulation of products of metabolism in the storage bags and other factors associated with platelets storage beyond 5 d could impact the system buffering capacity leading to the drop in pH observed in our study. This change in pH combined with the closed nature of the *ex vivo* system could also account for the observed effects. A second limitation is that *in vitro* testing of stored PLTs has limitations. While some PLTs functions are lost during storage, others may be recovered *in vivo* following transfusion. As suggested by Cardigan et al\[[@B51]\], changes observed in stored PLTs might not necessarily abrogate *in vivo* hemostatic activities. Whether storage of PCs in VitC truly affects hemostatic activities under *in vivo* conditions remains to be determined as a future endeavor.

COMMENTS
========

Background
----------

Vitamin C (VitC) is a key modulator of platelet (PLT) function. Platelets store high intracellular concentrations of VitC, which then modify its oxidative state and play a role in its ability to aggregate. High dose intravenous VitC is increasingly being used both by Complementary and Alternate Medicine practitioners and by licensed medical practitioners as adjunct therapy for wide ranging diseases including sepsis, sepsis induced acute lung injury, multiple cancers, iron deficiency in hemodialysis patients and burns. However, there is no information on the impact of high dose VitC on normal PLT function. To address this need, the authors examined the effect of exposing *ex vivo* human PLTs to high doses of VitC.

Research frontiers
------------------

It is well known that VitC is required for normal platelet function. While pre-clinical studies have examined changes in PLT function in disease and the impact of VitC on these functions, no studies have examined PLT function in the presence of such high doses of VitC.

Innovations and breakthroughs
-----------------------------

This is the first study to evaluate *ex vivo* PLT function in the presence of high concentrations of VitC. The innovative approach to use PLT storage bags afforded a reproducible system that allowed for gauging the temporal effects of high doses of VitC on PLT function.

Applications
------------

This study advises moderate levels of caution regarding the extended use of high doses of intravenous VitC. While these high doses have no deleterious impact on PLT function in the short term (up to 5 d), there appear to be unanticipated effects on PLT function as assessed by thromboelastography (TEG) after 8 d of continuous exposure.

Terminology
-----------

TEG, is a hemostatic assay that measures the viscoelastic properties (physical) of whole blood clot formation under low shear stress. It shows the interaction of platelets with the coagulation cascade (aggregation, clot strengthening, fibrin cross linking and fibrinolysis).
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